DK1140198T3 - Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad - Google Patents

Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad

Info

Publication number
DK1140198T3
DK1140198T3 DK00902481T DK00902481T DK1140198T3 DK 1140198 T3 DK1140198 T3 DK 1140198T3 DK 00902481 T DK00902481 T DK 00902481T DK 00902481 T DK00902481 T DK 00902481T DK 1140198 T3 DK1140198 T3 DK 1140198T3
Authority
DK
Denmark
Prior art keywords
hyaluronan
efficacy
enhancing
drug
manufacture
Prior art date
Application number
DK00902481T
Other languages
English (en)
Inventor
Tracey Brown
Original Assignee
Alchemia Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP8131A external-priority patent/AUPP813199A0/en
Priority claimed from AUPQ3938A external-priority patent/AUPQ393899A0/en
Application filed by Alchemia Oncology Pty Ltd filed Critical Alchemia Oncology Pty Ltd
Application granted granted Critical
Publication of DK1140198T3 publication Critical patent/DK1140198T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK00902481T 1999-01-13 2000-01-06 Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad DK1140198T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8131A AUPP813199A0 (en) 1999-01-13 1999-01-13 A composition and method for the enhancement of the efficacy of drugs
AUPQ3938A AUPQ393899A0 (en) 1999-11-09 1999-11-09 A composition and method for the enhancement of the efficacy of drugs
PCT/AU2000/000004 WO2000041730A1 (en) 1999-01-13 2000-01-06 A composition and method for the enhancement of the efficacy of drugs

Publications (1)

Publication Number Publication Date
DK1140198T3 true DK1140198T3 (da) 2008-03-10

Family

ID=25645970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00902481T DK1140198T3 (da) 1999-01-13 2000-01-06 Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad

Country Status (14)

Country Link
US (1) US8741970B2 (da)
EP (1) EP1140198B1 (da)
JP (2) JP4790911B2 (da)
KR (1) KR20010113642A (da)
CN (1) CN100374163C (da)
AT (1) ATE376824T1 (da)
CA (1) CA2370003C (da)
DE (1) DE60036915T2 (da)
DK (1) DK1140198T3 (da)
ES (1) ES2295005T3 (da)
HK (1) HK1041209A1 (da)
NZ (1) NZ512676A (da)
TW (1) TWI284042B (da)
WO (1) WO2000041730A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1443931B1 (en) * 2001-07-20 2007-03-28 Iomed, Inc. Ocular iontophoretic device for delivering methotrexate based medicaments and use thereof to treat neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
KR20030066927A (ko) * 2002-02-06 2003-08-14 구자영 쿠르쿠민과 5-프루오로유라실로 이루어진 항암제 및 이항암제의 용도
WO2004003545A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
AU2003291872A1 (en) * 2002-12-04 2004-06-23 Inrs (Institut National De Recherche Scientifique) An exopolysaccharides delivery system for active molecules
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA612307A (en) 1961-01-10 International Business Machines Corporation Hydraulic drive tape handling system
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS6117A (ja) 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
CA1227427A (en) * 1984-08-16 1987-09-29 Albert Landsberger Therapeutic agent for the use in cancer treatment
US5532341A (en) 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5202431A (en) 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4665107A (en) 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061703C (en) 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5977088A (en) 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6475795B1 (en) 1991-07-03 2002-11-05 Meditech Research, Ltd. Use of hyaluronan in gene therapy
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
CA2087621C (en) 1993-01-18 1996-08-20 Albin L. Vazza Livestock feed from potato waste
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2094203A1 (en) 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU2479695A (en) 1994-05-09 1995-11-29 Hadasit Medical Research Services & Development Company Ltd Prevention of tumor metastasis
AU3159595A (en) * 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
WO1997009998A2 (en) 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
JP2000513707A (ja) 1995-12-01 2000-10-17 ハイアル ファーマスティカル コーポレイション 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
DE69700887T2 (de) 1996-01-31 2000-06-29 Nisshin Flour Milling Co., Ltd. Isoprenderivate
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
IT1286510B1 (it) * 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
US6232301B1 (en) 1996-12-27 2001-05-15 Seikagaku Corporation Remedies for bladder disorders
DK0971961T3 (da) 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
CA2208924A1 (en) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
EP1117835A4 (en) 1998-10-02 2005-03-09 Genzyme Corp PREVENTION OF ADHERENCES
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306643B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
ATE312076T1 (de) 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
CA2458856C (en) 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
EP1480656A4 (en) 2002-02-15 2007-07-18 Res Dev Foundation ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения

Also Published As

Publication number Publication date
NZ512676A (en) 2003-01-31
CA2370003A1 (en) 2000-07-20
CA2370003C (en) 2008-08-19
US20130197103A1 (en) 2013-08-01
DE60036915T2 (de) 2008-08-07
WO2000041730A1 (en) 2000-07-20
EP1140198B1 (en) 2007-10-31
HK1041209A1 (zh) 2002-07-05
ATE376824T1 (de) 2007-11-15
EP1140198A1 (en) 2001-10-10
KR20010113642A (ko) 2001-12-28
TWI284042B (en) 2007-07-21
ES2295005T3 (es) 2008-04-16
EP1140198A4 (en) 2004-08-04
CN1336828A (zh) 2002-02-20
JP2011178802A (ja) 2011-09-15
US8741970B2 (en) 2014-06-03
DE60036915D1 (de) 2007-12-13
JP4790911B2 (ja) 2011-10-12
JP2002534484A (ja) 2002-10-15
CN100374163C (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
WO2005041936A3 (en) Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
ATE247965T1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
NO20073635L (no) Kombinasjonsbehandling for multippel sklerose
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
ZA200605900B (en) Glycosylated steroid derivatives with anti-migratory activity
UA92344C2 (ru) Топичная композиция, содержащая рыбный желатин
BR0207681A (pt) Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
ITRM940138A0 (it) Composizione farmaceutica ad azione antiflogistica, analgesica e biomodulatrice nei confronti di affezioni acute e croniche di parti molli e di sostegno osteoarticolare.